The first batch of biopharmaceutical enterprises in China to obtain GMP certification

Entering Tri-Prime Gene

Beijing Tri-Prime Gene Pharmaceutical Co, Ltd. (referred to as Tri-Prime Gene, stock code: 837344) is a modern pharmaceutical biotechnology enterprise with a registered capital of 121.81 million RMB. It is mainly engaged in the research, development, production, and sales of pharmaceutical biotechnology products, including gene engineering drugs, gene engineering vaccines, and diagnostic reagents. It also engages in related technical trade and technical consulting services.

Learn More
  •  
    +

    effective invention patents

  •  

    1992~2024

Deep cultivation in the field of interferon for 30 years

Product Center

Hapgen ® Spray

recombinant human interferon α1b spray

National "863" program and national "11th Five-Year Plan" major new drug innovation technology major project "Biological large varieties transformation projects", treating common skin viral infections - facial simplex herpes, promoting skin healing, reduc

Learn More

Hapgen ® eye drops

human interferon α1b eye drops

National "11th Five-Year Plan" Major New Drug Development and Manufacturing Technology Project "Biological Large Variety Reform Project", for the treatment of common acquired blindness diseases - simplex herpes virus keratitis.

Learn More

Hapgen ® powder injection

injected human interferon α1b

Class I new drug, national key new product, Beijing's major technological achievement promotion plan project. Treatment of viral infections and some malignant tumors.

Learn More

Hapgen® injection

Human interferon α1b injection

National key new product, Beijing's independent innovation product, Beijing's major high-tech achievement transformation project, Zhongguancun National Independent Innovation Demonstration Zone new technology, new product (service), treating viral infecti

Learn More

China's leading biopharmaceutical Company

Core technology

微信公众号

不良反应报告